Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: Critical role of methoxylation in both inhibition potency and cytotoxicity

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3193-3200

  Valdameri, Glaucio ^a,b   Gauthier, Charlotte ^a   Terreux, Raphaël ^a   Kachadourian, Rémy ^c   Day, Brian J ^c   Winnischofer, Sheila M B ^b   Rocha, Maria E M ^b   Frachet, Véronique ^d   Ronot, Xavier ^d   Di Pietro, Attilio ^a   Boumendjel, Ahcène ^d  

^a UNIVERSITÉ LYON 1   (France)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c DEPARTMENT OF MEDICINE   (United States)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 INDOLYL 3 PHENYLPROPENONE DERIVATIVE; 1 PHENYL 3 INDOLYLPROPENONE DERIVATIVE; ACETOPHENONE DERIVATIVE; BENZALDEHYDE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CHALCONE DERIVATIVE; ELACRIDAR; INDOLYLPHENYLPROPENONE DERIVATIVE; MITOXANTRONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL PROLIFERATION; CHALCONES; HEK293 CELLS; HUMANS; INDOLES; MODELS, MOLECULAR; NEOPLASM PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84859786879     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2016528     Document Type: Article

References (34)

1. Glavinas, H.; Krajcsi, P.; Cserepes, J.; Sarkadi, B. The role of ABC tansporters in drug resistance, metabolism and toxicity Curr. Drug Deliv. 2004, 1, 27-42
2. Allikmets, R.; Schriml, L. M.; Hutchinson, A.; Romano-Spica, V.; Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance Cancer Res. 1998, 58, 5337-5339
3. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15665-15670
4. Miyake, K.; Mickley, L.; Litman, T.; Zhan, Z.; Robey, R.; Cristensen, B.; Brangi, M.; Greenberger, L.; Dean, M.; Fojo, T.; Bates, S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes Cancer Res. 1999, 59, 8-13
5. Ahmed-Belkacem, A.; Pozza, A.; Macalou, S.; Perez-Victoria, J. M.; Di Pietro, A. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2) Anticancer Drugs 2006, 17, 239-243
6. Boumendjel, A.; Macalou, S.; Valdameri, G.; Pozza, A.; Gauthier, C.; Arnaud, O.; Nicolle, E.; Magnard, S.; Falson, P.; Terreux, R.; Carrupt, P.-A.; Payen, L.; Di Pietro, A. Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validation Curr. Med. Chem. 2011, 18, 3387-3401
7. Ahmed-Belkacem, A.; Pozza, A.; Munoz-Martinez, F.; Bates, S. E.; Castanys, S.; Gamarro, F.; Di Pietro, A.; Pérez-Victoria, J. M. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2 Cancer Res. 2005, 65, 4852-4860
8. Nicolle, E.; Boccard, J.; Guilet, D.; Dijoux, M.-G.; Zelefac, F.; Macalou, S.; Grosselin, J.; Schmidt, J.; Carrupt, P.-A.; Di Pietro, A.; Boumendjel, A. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation-energy approach Eur. J. Pharm. Sci. 2009, 38, 39-46
9. Nicolle, E.; Boumendjel, A.; Macalou, S.; Genoux, E.; Ahmed-Belkacem, A.; Carrupt, P.-A.; Di Pietro, A. QSAR analysis and molecular modeling of ABCG2-specific inhibitors Adv. Drug Pharm. Sci. 2009, 61, 34-46
10. Bois, F.; Beney, C.; Boumendjel, A.; Mariotte, A.-M.; Conseil, G.; Di Pietro, A. Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance J. Med. Chem. 1998, 41, 161-164
11. Bois, F.; Boumendjel, A.; Mariotte, A.-M.; Conseil, G.; Di Pietro, A. Synthesis and biological activity of 4-alkoxychalcones: potential hydrophobic modulators of P-glycoprotein-mediated multidrug resistance Bioorg. Med. Chem. 1999, 7, 2691-2695
12. Liu, X.-L.; Tee, H.-W.; Go, M.-L. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein Bioorg. Med. Chem. 2008, 16, 171-180
13. Han, Y.; Riwanto, M.; Go, M.-L.; Ee, P. L. R. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues Eur. J. Pharm. Sci. 2008, 35, 30-41
14. Juvale, K.; Pape, V. F. S.; Wiese, M. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein Bioorg. Med. Chem. 2012, 20, 346-355
15. Boumendjel, A.; McLeer-Florin, A.; Champelovier, P.; Allegro, D.; Muhammad, D.; Souard, F.; Derouazi, M.; Peyrot, V.; Toussaint, B.; Boutonnat, J. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro glioblastoma models BMC Cancer 2009, 9, 242
16. Rabindran, S. K.; He, H.; Singh, M.; Brown, E.; Collins, K. I.; Annable, T.; Greenberger, L. M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C Cancer Res. 1998, 58, 5850-5858
17. van Loevezijn, A.; Allen, J. D.; Schinkel, A. H.; Koomen, G. J. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines Bioorg. Med. Chem. Lett. 2001, 11, 29-32
18. Allen, J. D.; van Loevezijn, A.; Lakhai, J. M.; van der Valk, M.; van Tellingen, O.; Reid, G.; Schellens, J. H. M.; Koomen, G. J.; Schinkel, A. H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C Mol. Cancer Ther. 2002, 1, 417-425
19. Boumendjel, A.; Boccard, J.; Carrupt, P.-A.; Nicolle, E.; Blanc, M.; Geze, A.; Choisnard, L.; Wouessidjewe, D.; Matera, E. L.; Dumontet, C. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship J. Med. Chem. 2008, 51, 2307-2310
20. Martel-Frachet, V.; Kadri, M.; Boumendjel, A.; Ronot, X. Structural requirement of arylindolylpropenones as anti-bladder carcinoma cells agents Bioorg. Med. Chem. 2011, 19, 6143-6148
21. Harborne, J. B.; Williams, C. A. Advances in flavonoid research since 1992 Phytochemistry 2000, 55, 481-504
22. Kachadourian, R.; Day, B. J.; Pugazhenti, S.; Franklin, C. C.; Genoux-Bastide, E.; Mahaffey, G.; Gauthier, C.; Di Pietro, A.; Boumendjel, A. A synthetic chalcone as a potent inducer of glutathione biosynthesis J. Med. Chem. 2012, 55, 1382-1388
23. Valdameri, G.; Genoux-Bastide, E.; Peres, B.; Gauthier, C.; Guitton, J.; Terreux, R.; Winnischofer, S. M. B.; Rocha, M. E. M.; Boumendjel, A.; Di Pietro, A. Substituted chromones as highly-potent, nontoxic inhibitors, specific for the breast cancer resistance protein ABCG2 J. Med. Chem. 2012, 55, 966-970
24. Valdameri, G.; Pereira Rangel, L.; Sapatafora, C.; Guitton, J.; Gauthier, C.; Arnaud, O.; Ferreira-Pereira, A.; Falson, P.; Winnischofer, S. M. B.; Rocha, M. E. M.; Tringali, C.; Di Pietro, A. Methoxy stilbenes as potent, specific, untransported and noncytotoxic inhibitors of breast cancer resistance protein ACS Chem. Biol. 2012, 7, 322-330
25. Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-gp responsible for cancer cell multidrug resistance Med. Res. Rev. 2002, 22, 512-529
26. Macalou, S.; Ahmed-Belkacem, A.; Borelli, F.; Capasso, R.; Fattorusso, E.; Taglialatela-Scafati, O.; Di Pietro, A. Non-prenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors J. Med. Chem. 2007, 50, 1933-1938
27. Boumendjel, A.; Macalou, S.; Ahmed-Belkacem, A.; Blanc, M.; Di Pietro, A. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2 Bioorg. Med. Chem. 2007, 15, 2892-2897
28. Arnaud, O.; Boumendjel, A.; Gèze, A.; Honorat, M.; Matera, E. L.; Guitton, J.; Stein, W. D.; Bates, S. E.; Falson, P.; Dumontet, C.; Di Pietro, A.; Payen, L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan Eur. J. Cancer 2011, 47, 640-648
29. Robey, R. W.; Honjo, Y.; Van de Laar, A.; Miyake, A.; Regis, J. T.; Litman, T.; Bates, S. E. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2) Biochim. Biophys. Acta: Biomembranes 2001, 1512, 171-182
30. Mosmann, T. Rapid colorimetric assay for cellular growth and survival. Application to proliferation and cyto-toxicity assays J. Immunol. Methods 1983, 65, 55-63
31. SYBYL-X 1.3, Tripos International, St. Louis, MO 63144, USA.
32. Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries J. Comput. Chem. 1999, 7, 730-748
33. Cramer, R. D., III; DePriest, S. A.; Patterson, D. E.; Hecht, P. The Developing Practice of Comparative Molecular Field Analysis in 3D QSAR in Drug Design: Theory, Methods and Applications; ESCOM: Leiden, The Netherlands, 1993.
34. Picard, R.; Cook, D. Cross-validation of regression models J. Am. Stat. Assoc. 1984, 79, 575-583